NASDAQ · Stocky rates: Cautious

Bio-Techne Corporation (TECH)

$72.58 ▲ +0.25% as of 5 Oct, 20:00

Stocky turns companies like Bio-Techne Corporation into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.

Try Stocky free →
55
/ 100
Neutral

What Stocky thinks

Stocky rates Bio-Techne Corporation at 55/100 based on business quality, leadership alignment, valuation.

Compounder Score
49/100
Business quality — profitability, growth, capital efficiency.
Moat Score
53/100
Competitive advantage — pricing power, switching costs, network effects.
Resilience
100/100
Downside resilience — customer concentration, supply chain, refinancing risk.
Value Score
45/100
Valuation vs peers and history — is this a good price to pay?
A+
Very strong — very safely financed, with steady profits and cash.

How safely Bio-Techne Corporation is financed, graded A++ (strongest) to C from the last five years of accounts: debt against earnings, interest cover, cash against debt, how high and steady profit margins are, return on capital, and whether it generated cash every year. Not part of the Stocky score.

What Stocky gives investors that other tools don't

Every stock is scored across six dimensions built to answer one question — can this business keep compounding? — without a Bloomberg subscription. Here's the actual snapshot for Bio-Techne Corporation:

55
VERDICT

Stocky Verdict — one score, everything

Quality + moat + leadership + valuation fused into a single 0–100 number. When you see 55/100, you know instantly whether to dig deeper or skip.

Narrow
MOAT

Moat Score — is there a real edge?

Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.

—
LEADER

Leadership Alignment — is management on your side?

Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.

100
RESILIENCE

Resilience Profile — what could break?

Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.

Elite
TRACK

Track Record — does the system work?

We don't claim a backtest. The top-scoring basket is recorded every month and measured against the S&P 500 from that date onward — judged on what it said before the outcome was known. The record is young, and published as it stands.

24/7
ALERTS

Alerts + Portfolio insights

Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.

Bio-Techne Corporation (TECH) — frequently asked

Is Bio-Techne Corporation (TECH) a good investment right now?

Stocky rates Bio-Techne Corporation (TECH) at 55/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation into a single number.

What is TECH's Stocky Verdict?

TECH's current Stocky Verdict is 55/100, placing it in the "Cautious" band. This composite combines a 49/100 Compounder score, Leadership, 53/100 Moat rating.

Does Bio-Techne Corporation have a competitive moat?

Bio-Techne Corporation rates Narrow moat (53/100 Moat Score) — based on 10-year return-on-invested-capital, pricing power, switching costs and network effects. Wide moats compound; Limited moats erode.

Is Bio-Techne Corporation's leadership aligned with shareholders?

Leadership Alignment for Bio-Techne Corporation is under analysis. Stocky scores founder tenure, insider ownership, CEO compensation multiple-of-salary, and long-term shareholder value creation.

What are the biggest risks to TECH?

Bio-Techne Corporation's Resilience Profile scores 100/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to Bio-Techne Corporation.

This is just the surface. See the whole picture on Bio-Techne Corporation.

Sign up free and unlock the full analysis on TECH — the same tools professional analysts use, personalised to your portfolio:

  • Every analyst covering TECH — full list with star ratings, price targets, historical hit-rate. Not just the top 3 you see above.
  • Full Resilience Profile — customer concentration, refinancing walls, stress-test scenarios (-20% revenue, +200bp rates) modelled specifically for TECH.
  • Bull & bear thesis — the AI-written counter-argument every retail investor forgets to read.
  • Portfolio fit check — how TECH changes your sector concentration, correlation and Verdict-weighted quality.
  • Ask Stocky AI — "What are the biggest 3-year risks to TECH?" · "Is TECH overvalued vs its 5-year median?" · unlimited follow-ups on your portfolio.
  • Live alerts — analyst target changes, insider buys, big moves — the day they happen.
Start free · 14 days Plus, no card →

Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.

STOCKY VERDICT
55
/ 100 · Neutral

See Bio-Techne Corporation the Stocky way

This page is just a preview. Open the live, interactive version for the full picture:

Stocky Verdict
A plain-English Buy / Hold / Sell score out of 100.
Compounder & Value scores
How strong the business is — and whether it looks cheap.
Interactive charts
1M to 5Y price history with company events plotted on it.
Top analyst targets
What the best-rated Wall Street analysts expect next.
What if? simulator
See what an investment in TECH would be worth today.
Practice portfolio
Buy TECH with virtual money and track it — zero risk.
Free · no real money · learn by doing Open TECH in Stocky →

Or jump straight to the interactive dashboard for TECH in the app.